FDA approves daraxonrasib, a breakthrough drug for pancreatic cancer

The US Food and Drug Administration has approved daraxonrasib, a new treatment for pancreatic cancer, one of the world's deadliest malignancies. Experts have described the drug as a game changer in oncology. Pancreatic cancer has long had extremely poor survival rates and very limited treatment options.